Says “confident” in expectations for 2025 and beyond. Comments taken from Q3 earnings conference call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson’s nipocalimab shows disease control in myasthenia gravis
- Options Volatility and Implied Earnings Moves Today, October 15, 2024
- Johnson & Johnson reports Q3 adjusted EPS $2.42, consensus $2.21
- Johnson & Johnson cuts FY24 adjusted EPS to $9.86-$9.96 from $10.00-$10.10
- Johnson & Johnson: Q3 Innovative Medicine worldwide operational sales up 6.3%
Questions or Comments about the article? Write to editor@tipranks.com